Source comparison
Stacking Thymosin Alpha-1 BPC-157 Lyme Research: Peptide Comparison
Thymosin Alpha-1 TLR9 agonist, Th1 cytokine upregulation, T-cell differentiation Immune dysregulation, CD4+ suppression, IFN-γ deficiency 1.6–3.2mg SC 2–3x/week ~2 hours Phase III data in sepsis, Phase II in chronic viral infections BPC-157 VEGF upregulation,
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- TLR9 agonist, Th1 cytokine upregulation, T-cell differentiation
- Immune dysregulation, CD4+ suppression, IFN-γ deficiency
- 1.6–3.2mg SC 2–3x/week
- ~2 hours
- Phase III data in sepsis, Phase II in chronic viral infections
- BPC-157
- VEGF upregulation, angiogenesis, MMP-9 inhibition, collagen synthesis
- Joint inflammation, neuropathy, vascular damage, soft tissue lesions
- 250–500mcg SC daily
- <4 hours
- Preclinical models (tendon, GI, vascular), case series in PTLDS
- Combined Stack
- Immune modulation + tissue repair
- Dual pathology: immune dysfunction and chronic tissue inflammation
- TA1 1.6mg 2x/week + BPC-157 500mcg daily
- N/A
- Case series (n=47) in PTLDS, no RCTs published